This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Deep vein thrombosis (DVT); venous thromboembolism (VE)	Thrombin (factor IIa; F2)	<i>In vitro</i> and mouse studies identified a nonpeptide thrombin inhibitor that could be used as an anticoagulant to help treat DVT and VTE. <i>In vitro</i> , a 1-(pyridine-4-yl)piperidine-4-carboxamine-based compound selectively inhibited human thrombin with low nanomolar K_i values over factor Xa and other serine proteases. In a clotting assay in human plasma, the inhibitor had anticoagulant activity at low micromolar concentrations. Next steps could include testing the anticoagulant in additional animal studies.	Patent and licensing status unavailable	De Candia, M. <i>et al. J. Med. Chem.</i> ; published online Oct. 8, 2013; doi:10.1021/jm401169a Contact: Cosimo Altomare, University of Bari Aldo Moro, Bari, Italy e-mail: cosimodamiano.altomare@uniba.it
SciBX 6(44); doi:10.1038/scibx.2013.1254 Published online Nov. 14, 2013				